Health Catalyst, Inc.

Health Catalyst, Inc. Q4 FY2020 earnings

HCAT

Quarter ended Dec 2020.

← Q3 FY2020Q1 FY2021 →
Revenue
$53.3M
+22.5% YoY
Operating margin
-73.0%
-41.6 pp YoY
Net income
-$43.0M
-201.5% YoY

Summary

Health Catalyst closed FY2020 with fourth-quarter revenue of $53.28 million, up 22.5% from the prior-year quarter. Full-year revenue reached $188.84 million, up 21.9%. The top line benefited from new DOS Subscription Customers, acquired technology customers, and contractual annual escalators on existing technology access fees. Growth came with heavier losses. The fourth-quarter operating loss was $38.92 million, and that loss widened. The full-year operating loss was $96.12 million and also widened. Net loss was $43.02 million in the quarter, with the loss widening. For the full year, net loss was $115.02 million and the loss widened. Diluted EPS for the full year was -$2.91, and that loss narrowed from the prior-year year-to-date period. Operating margin was -73.1% in the quarter, down from the prior-year quarter, and -50.9% for the full year, down from the prior-year year-to-date period.

Cash generation improved even as losses grew. Operating cash flow was -$4.14 million in the fourth quarter, up from the prior-year quarter. For the full year, operating cash flow was -$26.15 million, up 18.8%. Capital expenditures were $5.70 million in the quarter, up from the prior-year quarter, and $7.78 million for the full year, up 285.9%. Deferred revenue ended the year at $49.00 million, up 52.6%. Remaining performance obligations were $89.40 million, up 63.7%. Non-GAAP measures told a better story on profitability. Fourth-quarter Adjusted EBITDA was -$4.694 million, versus -$6.488 million a year earlier, and full-year Adjusted EBITDA was -$21.287 million. Total Adjusted Gross Margin was 52% in the quarter, and Adjusted Professional Services Gross Margin fell to 25% for the full year from 35% in 2019.

Operational metrics were mixed. Health Catalyst counted 74 DOS Subscription Customers at December 31, 2020, up from 65 a year earlier. The Dollar-based Retention Rate was 102% for 2020, down from 109% for 2019, and management tied the decline to lower professional services retention caused by COVID-19 financial strain on customers. Technology dollar-based retention saw minimal impact. The company served over 300 Other Customers at year end, compared with 65 at December 31, 2019, largely because of the Able Health, Healthfinch, and Vitalware acquisitions. Vitalware's Chargemaster Management product was ranked Best in KLAS for 2020, the third straight year for the Vital-CDM product. The board named Timothy G. Ferris as Chair effective March 1, 2021, succeeding Fraser Bullock. The company ended 2020 with more than 1,000 team members and said customer usage of its data platform rose meaningfully during the year.

Guidance points to continued top-line expansion but still negative Adjusted EBITDA. For the first quarter of 2021, Health Catalyst guides to total revenue, a GAAP measure, and to Adjusted EBITDA between -$3.9 million and -$1.9 million. For the full year of 2021, it guides to total revenue and to Adjusted EBITDA between -$16.0 million and -$13.5 million. The company has not reconciled the Adjusted EBITDA guidance to net loss because items such as stock-based compensation are outside its control or cannot be reasonably predicted. Risks include continued COVID-19 uncertainty, strain on professional services retention, cautious purchasing by health systems, acquisition integration costs, expected flat to declining revenue from Medicity customers, and a headwind from moving customers to Microsoft Azure.

Forecast

Management guidance
ReportedGuidance

Guided revenue, Q1 FY2021$53.0M – $56.0M
Midpoint$54.5M
Growth vs Q4 FY2020+2.3%
Growth vs Q1 FY2020+20.8%
Q1 2021
Adjusted EBITDA$(3.9) million - $(1.9) million
Full Year 2021
Total revenue$225.1 million - $228.1 million
Adjusted EBITDA$(16.0) million - $(13.5) million

Reported figures

GAAP, from SEC filings
MetricQ4 FY2020Q3 FY2020QoQQ4 FY2019YoY
Revenue$53.3M$47.2M+12.9%$43.5M+22.5%
Research & development$15.0M$13.4M+11.9%$13.0M+14.8%
Sales & marketing$14.8M$14.6M+1.1%$11.7M+26.4%
General & administrative$28.1M$13.3M+111.5%$8.4M+235.7%
Total operating expenses$65.7M$46.3M+41.9%$35.5M+85.0%
Operating income (loss)-$38.9M-$23.5M-65.9%-$13.7M-184.7%
Operating margin-73.0%-49.7%-23.3 pp-31.4%-41.6 pp
Net income (loss)-$43.0M-$27.3M-57.4%-$14.3M-201.5%
Net margin-80.7%-57.9%-22.8 pp-32.8%-47.9 pp

Risks

HIGHCOVID-19 Impact

COVID-19 disrupted healthcare provider customers and may continue to create near-term financial uncertainty and cautious purchasing decisions. The filing states the financial strain led to meaningfully lower professional services dollar-based retention and Adjusted Professional Services Gross Margin decreased from 35% for 2019 to 25% for 2020.

HIGHSales Cycle

The sales cycle for a new customer has averaged approximately one year and in some cases has exceeded two years, and COVID-19 could lengthen it. MD&A reports 2020 DOS Subscription Customer additions of nine were lower than the historical annual number of additions due to the impact of COVID-19 on sales achievement during the first half of 2020.

HIGHRetention Risk

Growth depends on renewal of existing customer contracts and sales of additional technology and services, and most customers have no obligation to renew after the initial term. The Dollar-based Retention Rate was 102% for 2020 compared with 109% for 2019, and the filing expects continued strain on professional services dollar-based retention in the near term.

HIGHMargin Pressure

Adjusted Professional Services Gross Margin decreased from 35% for 2019 to 25% for 2020, and Total Adjusted Gross Margin was 50% for 2020 compared with 52% for 2019. Drivers include lower professional services dollar-based retention, temporary COVID-19 related discounts, and changes in professional services mix.

HIGHCompetition

The market for healthcare solutions is intensely competitive, and the company faces competition from industry-agnostic analytics companies and EHR companies such as Epic Systems and Cerner. Larger competitors such as Optum Analytics and IBM have greater name recognition, longer operating histories, and significantly greater resources, and increased competition is likely to result in pricing pressures.

HIGHProduct Liability

Analytics applications may be used for clinical decision-making, treatment protocols, and care delivery prioritization. If analyses are incorrect, incomplete, or associated with faulty clinical decisions, the company could face medical malpractice or product liability claims, and insurance may not be sufficient to cover large awards.

MEDIUMAcquisition Integration

The company acquired Able Health, Healthfinch, and Vitalware in 2020 and is integrating them, with integration-related and duplicative costs expected to affect the near-term operating cost profile. Medicity customers have generated a lower Dollar-based Retention Rate than DOS Subscription Customers and revenue from Medicity customers is expected to be flat to declining.

MEDIUMCustomer Concentration

The three largest customers during 2020 comprised 5.6%, 4.6%, and 3.9% of revenue, or 14.1% in the aggregate, compared with 11.8% in the aggregate during 2019. The loss, termination, or renegotiation of any largest customer contract could adversely affect results.

MEDIUMHosting Transition

The company is transitioning customers from its private data center and on-premise DOS deployments to Microsoft Azure, which is more costly on a per-customer basis. MD&A expects this to result in higher cost of technology revenue and a headwind against increases in Adjusted Technology Gross Margin.

MEDIUMTalent Retention

Several senior leaders are active members of the Church of Jesus Christ of Latter-Day Saints, and one co-founder, Steven Barlow, previously took a leave of absence for a full-time church call from 2017 to 2020. The loss or leave of key executives could disrupt the business and delay business objectives.

MEDIUMDebt Counterparty

The company issued $230.0 million of 2.50% Convertible Senior Notes due 2025 and entered into capped call transactions with option counterparties. If an option counterparty becomes subject to insolvency proceedings, the company would become an unsecured creditor and could suffer dilution or adverse tax consequences.

MEDIUMHealthcare Industry Change

Changes in the healthcare industry, including the increasing market share of EHR companies in data analytics at hospital systems and customer or vendor consolidation, could cause existing contracts to be terminated or make new contracts harder to negotiate on acceptable terms. The filing states these trends could reduce revenue and make it difficult to maintain or expand the customer base.

MEDIUMPricing Risk

The company has adjusted prices and began introducing new pricing for new customers in the fourth quarter of 2018, and it may need to continue to adjust its pricing model. Its pricing assessments may be inaccurate, and inefficient pricing could harm results and future performance.

Dollar-based Retention Rate (FY2020)
102%
DOS Subscription Customers (as of December 31, 2020)
74
Other Customers (as of December 31, 2020)
over 300
Recurring Revenue as a percentage of total revenue (FY2020)
greater than 90%
Adjusted EBITDA (Q4 2020)
$ (4,694) (in thousands)
Total Adjusted Gross Margin (Q4 2020)
52%
Adjusted Technology Gross Margin (Q4 2020)
68%
Adjusted Professional Services Gross Margin (Q4 2020)
27%

Adjusted EBITDA

23 quarters
-$4.7M
Q4 FY2020-27.0%

Adjusted Professional Services Gross Margin

16 quarters
27%
Q4 FY2020+6.0pp

Adjusted Technology Gross Margin

16 quarters
68%
Q4 FY2020-1.0pp

Total Adjusted Gross Margin

15 quarters
52%
Q4 FY2020+3.0pp

DOS Subscription Customers

3 quarters
74
Q4 FY2020+13.8%

Summary, forecast, risks and KPIs are extracted from Health Catalyst, Inc.'s SEC filings for Q4 FY2020 (10-Q / 10-K and the 8-K earnings release); GAAP figures in the summary are checked against the reported XBRL data. They can contain errors; the filings are authoritative. Processed Oct 21, 2026.